undamentalytics Newsletter
Sign in

Ensysce Biosciences, Inc. balance sheet

At the end of fiscal 2025, Ensysce Biosciences, Inc. had total assets of $7.5m, total liabilities of $4.6m and shareholders' equity of $3.2m. It held $4.3m in cash against $306,708 of debt: net cash of $4.0m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents01231441
Total current assets01652573
Total assets01663673
Accounts payable2032132
Total current liabilities71693254
Long-term debt140————
Total debt5175—000
Total liabilities725103254
Shareholders' equity−6−8−4−043−1
Non-controlling interests and other (assets − liabilities − equity)−0—−0−0−0−0−0
Net debt (negative = net cash)551−1−3−4−0
Shares outstanding16m18m————16m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ENSC vs OCGNENSC vs TRDACRIS vs ENSCCAMP vs ENSC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ensysce Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ensysce Biosciences, Inc.